Hasil Pencarian (14063)
Halaman 46 / 282Deskripsi belum tersedia.
Deskripsi belum tersedia.
Deskripsi belum tersedia.
Deskripsi belum tersedia.
A specific inhibitor of phosphoserine/threonine protein phosphatase 1 and 2a. It is also a potent tumor promoter. (Thromb Res 1992;67(4):345-54 & Cancer Res 1993;53(2):239-41)
9-(4-hydroxybutyl)-N2-phenylguanine is a solid. This compound belongs to the hypoxanthines. These are compounds containing the purine derivative 1H-purin-6(9H)-one. 9-(4-hydroxybutyl)-n2-phenylguanine is known to target thymidine kinase.
9-(N-methyl-L-isoleucine)-cyclosporin A (NIM811) has been used in trials studying the treatment of Chronic Hepatitis C Genotype-1 Relapse.
Aminocamptothecin has been used in trials studying the treatment of Lymphoma, Gastric Cancer, Ovarian Cancer, Esophageal Cancer, and Ovarian Neoplasms, among others.
Deskripsi belum tersedia.
Deskripsi belum tersedia.
Deskripsi belum tersedia.
Deskripsi belum tersedia.
9 Cuab30 has been used in trials studying the treatment and prevention of HER2/Neu Positive, HER2/Neu Negative, No Evidence of Disease, Estrogen Receptor Negative, and estrogen receptor positive, among others.
?-Methylacetylfentanyl is an analog of fentanyl with opioid analgesic properties. It was categorized under the Schedule I in the US and it was illegally sold in early 1980. ?-Methylacetylfentanyl synthesis process is very similar to ?-methylfentanyl with the …
?A?–Gas6 is a chimeric fusion protein being investigated in preclinical studies as an immunotherapeutic agent for Alzheimer's disease (AD). It is made of a single chain variable fragment (scFv) of an Amyloid ? (A?)-targeting monoclonal antibody fused with a t…
Deskripsi belum tersedia.
Deskripsi belum tersedia.
A-dmDT390-bisFv(UCHT1) is under investigation in clinical trial NCT02943642 (Safety and Effectiveness of A-dmdt390-bisfv(ucht1) Fusion Protein in Subjects With Mycosis Fungoides).
A166 is an antibody-drug conjugate composed of a novel cytotoxic drug (Duo-5, anti-microtubule agent) site-specifically conjugated to an anti-HER2 antibody (trastuzumab) via a stable protease-cleavable valine citrulline linker.
AAV1-FS344 is an investigational gene therapy developed by Milo Biotechnology to deliver follistatin, a potent myostatin inhibitor. It is being investigated for the treatment of Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, and inclusion body myosit…